SLAMF7 and neoplasm: CS-1 was manipulated to improve therapeutic efficacy as well as prevent fratricide in CAR-T cells (119); however, deletion of CS-1 only protected the CAR-T cells from fratricide but did not enhance tumor control compared to CS-1-expressing CAR-T cells.